DNM0904 is a novel antibiotic developed by DeNovaMed effective against Gram-negative bacteria. It has shown to perform exceptionally well versus multi-drug and colistin resistant strains. In tests, we determined the Minimum Inhibitory Concentration (MIC) of Colistin and Colistin/DNM0904 for battling E. coli, K. pneumoniae, and A. baumannii. The MIC results for Colistin/DNM0904 were <0.03 in all cases, indicating highly effective performance.
Our ultimate goal is to leverage the strength of DNM0904 in combination with colistin to combat rising bacterial resistance and provide relief in terms of global economic loss and prevent potential setbacks in public health and industries. DNM0904 has been optimized for application in complex cases where other existing antibiotics are ineffective, bolstering our medical arsenal’s strength and responsiveness in future health-related crises.